News entries 12th October to 19th November
Testing medications on animals means drug trials and drug releases littered with surprises. This isn't an occasional event, it is commonplace.
“Propoxyphene:
Withdrawal - Risk of Cardiac Toxicity. Sold as Darvon, Darvocet, and generics.”
FDA Medwatch. 19 November 2010
“Heart
drug Multaq linked with 387 reports of adverse effects.”
Sacramento Bee. 19 November 2010.
“Study
of Pfizer, Bristol drug halted by bleeding.”
Reuters. 19 November 2010.
“Heart
drug raises questions. Report links Multaq with 387 reports of adverse effects.”
JS Online. 19 November 2010
“Health
Canada announces restrictions on diabetes drug due to heart risks.”
Winnipeg Free Press. 18 November 2010
“ResVerlogix
cholesterol drug fails mid-stage trial.”
Reuters. 17 November 2010.
“Weight
loss drug 'caused death of 500 people'.”
Daily Telegraph. 16 November 2010.
“France:
Diabetes drug may be linked to 500 deaths.”
Google. 16 November 2010.
“Major
new study shows Natrecor is safe, but not very effective.”
LA Times. 14 November 2010.
“October
2010 Safety Labeling Changes.
This posting includes 34 products with safety labeling changes to the following
sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE
REACTIONS, PATIENT PACKAGE INSERT, and MEDICATION GUIDE. The "Summary
Page" provides a listing of drug names and safety labeling sections
revised.”
FDA Medwatch. 13 November 2010
“Blood-clotting
drug given to wounded soldiers can cause heart attacks. Trials of NovoSeven,
used to halt blood loss, suggest it is no more effective than placebo and
raises risk of clots in arteries.”
The Guardian. 13 November 2010
“Acne linked to suicide risk. Acne drugs may
make things worse, say scientists.”
The Guardian. 12 November 2010.
“Study
on acne suicide risk fuels debate over drugs.”
Reuters. 12 November 2010.
“Lung
cancer drug experiment fails.”
Huliq. 11 November 2010.
“Suicide attempts in people taking isotretinoin
for acne. Are increased, but the risk is difficult to separate from the
higher risk associated with the condition itself.”
BMJ 11 November 2010
“Study links painkillers to reproductive disorders.”
Reuters. 8 November 2010.
“Drugs
linked to brain damage 30 years ago. MPs and campaigners predict class action
after failures to mount full-scale research into warnings left millions
of patients at risk.”
The Independent on Sunday. 7 November 2010.
“..the
DSMB recommended that the trial be halted because mortality in the rivastigmine
group (n=12, 22%) was higher than in the placebo group (n=4, 8%; p=0·07).
Median duration of delirium was longer in the rivastigmine group (5·0
days, IQR 2·7—14·2) than in the placebo group (3·0
days, IQR 1·0—9·3; p=0·06).”
Effect of rivastigmine as an adjunct to usual care with haloperidol on duration
of delirium and mortality in critically ill patients: a multicentre, double-blind,
placebo-controlled randomised trial The
Lancet, Early Online Publication, 5 November 2010
“Haemophilia
drug can damage heart - study.”
TVNZ. 4 November 2010.
“Are
YOUR pills dangerous?”
Daily Mail. 2 November 2010.
“Why the FDA Keeps Saying 'No' to Diet Pills.”
Seeking Alpha. 1 November 2010
“Novartis
Officials Hid Bone Drugs' Risks, Lawyer Tells Jurors.”
Bloomberg. 1 November 2010.
“Firm with Earth City unit is settling
suits over drugs tied to suicides.”
STLToday. 30 October 2010.
“Codeine
painkillers may be 'unsafe, addictive and ineffective'.”
Daily Mail. 23 October 2010.
“GnRH
Agonists: Label Change - Increased Risk of Diabetes and Cardiovascular Disease
(Update).”
FDA Medwatch. 22 October 2010.
“Federal prosecutors probing Glaxo diabetes
pill.”
Sacramento Bee. 21 October 2010
“More
diabetes drug woe for Lilly as teplizumab fails.”
Pharma Times. 21 October 2010.
“Women
Are Dying From Hormone Therapy; Why Is Pharma Still Allowed to Push It?”
Alternet. 21 October 2010.
“September 2010 Safety Labeling Changes:
37 Medical Product Labels with changes to Warnings, Contraindications, Precautions,
Adverse Reactions”
FDA Medwatch. 21 October 2010.
“FDA
warns of prostate cancer drug risks.”
Reuters. 20 October 2010.
“Hormone therapy raises breast cancer deaths:
study.”
Reuters. 20 October 2010.
“Drug companies lied to women about HRT risks for nine years”
Journal of the American Medical Association, 2010; 304: 1684-92 20 October
2010
“Pfizer wins HRT trial as new study knocks safety.”
Fiercepharma. 20 October 2010.
“Eli
Lilly diabetes drug fails to meet endpoint.”
Marketwatch. 20 October 2010
“Some
drugs raising red flags. Illinois doctors are speaking on behalf of pharmaceutical
companies, but some of the drugs they're speaking about have come under
investigation.”
Chicago Tribune. 18 October 2010
“Should long-term drugs get greater scrutiny?”
Fiercepharma. 18 October 2010.
“Glaxo
ready for barrage of lawsuits”
Fiercepharma. 18 October 2010.
“Experts admit swine flu jab 'may cause' deadly
nerve disease.”
Daily Mail. 16 October 2010
“FDA
warns of fractures with osteoporosis drugs.”
TMC. 16 October 2010.
“Doubts
over popular drug.” [reboxetine]
The Age. 15 October 2010.
“F.D.A.
Issues Warning on Bone Drugs.”
New York Times. 13 October 2010.
“Boehringer
Ingelheim withdraws libido drug for women”
BMJ 341:c5701 doi: 10.1136/bmj.c5701. 12 October 2010
Related Articles:
